4 transcripts
ABBV
Earnings call transcript
NYSE
2024 Q2
25 Jul 24
and innovative mechanisms that can elevate the standard of care in immunology, oncology and neuroscience.
In summary, I'm very pleased with the strong
ABBV
Earnings call transcript
NYSE
2024 Q1
26 Apr 24
innovative new medicines for patients will continue to fuel our robust pipeline for years to come. After a multiyear process, our Board has unanimously
ABBV
Earnings call transcript
NYSE
2023 Q4
2 Feb 24
through investments in our customers, consumers and innovation. As such, we anticipate aesthetics will be a strong growth portfolio for years to come
ABBV
Earnings call transcript
NYSE
2023 Q2
27 Jul 23
commercial investment and continued innovation to support robust long-term growth.
Given the strong and balanced performance across our diverse portfolio
- Prev
- 1
- Next